Clinical Trial

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary objective of this trial is to evaluate ovarian suppression following treatment with ZOLADEX 10.8 mg by luteinizing hormone (LH).
Protocol Amendment History 4 changes
notable Trial sites expanded: 15 -> 20 locations 2026-08-05
notable Trial sites expanded: 11 -> 15 locations 2026-07-15
critical Recruitment opened 2026-05-19
notable Trial sites expanded: 3 -> 10 locations 2026-05-19
Trial Details
NCT Number NCT07310420
Lead Sponsor TerSera Therapeutics LLC
Conditions Advanced Breast Cancer
Enrollment 88 participants
Start Date 2026-08-30
Primary Completion 2026-11-30 (estimated)
Study Completion 2027-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-04